- Home
- LTRN vs NRXP Comparison
LTRN vs NRXP Comparison
Compare LTRN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- NRXP
- Stock Information
- Founded
- LTRN 2013
- NRXP 2015
- Country
- LTRN United States
- NRXP United States
- Employees
- LTRN N/A
- NRXP N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- NRXP Health Care
- Exchange
- LTRN Nasdaq
- NRXP Nasdaq
- Market Cap
- LTRN 38.0M
- NRXP 34.7M
- IPO Year
- LTRN 2020
- NRXP N/A
- Fundamental
- Price
- LTRN $3.73
- NRXP $1.98
- Analyst Decision
- LTRN Buy
- NRXP Strong Buy
- Analyst Count
- LTRN 2
- NRXP 4
- Target Price
- LTRN $25.00
- NRXP $28.25
- AVG Volume (30 Days)
- LTRN 43.8K
- NRXP 128.2K
- Earning Date
- LTRN 05-08-2025
- NRXP 05-13-2025
- Dividend Yield
- LTRN N/A
- NRXP N/A
- EPS Growth
- LTRN N/A
- NRXP N/A
- EPS
- LTRN N/A
- NRXP N/A
- Revenue
- LTRN N/A
- NRXP N/A
- Revenue This Year
- LTRN N/A
- NRXP N/A
- Revenue Next Year
- LTRN N/A
- NRXP N/A
- P/E Ratio
- LTRN N/A
- NRXP N/A
- Revenue Growth
- LTRN N/A
- NRXP N/A
- 52 Week Low
- LTRN $2.55
- NRXP $1.10
- 52 Week High
- LTRN $7.21
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- LTRN 55.76
- NRXP 48.76
- Support Level
- LTRN $3.00
- NRXP $1.85
- Resistance Level
- LTRN $3.71
- NRXP $1.97
- Average True Range (ATR)
- LTRN 0.36
- NRXP 0.16
- MACD
- LTRN 0.08
- NRXP 0.03
- Stochastic Oscillator
- LTRN 85.51
- NRXP 71.43
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.